Company News: Page (1) of 1 - 05/11/18 Email this story to a friend. email article Print this page (Article printing at page facebook

Eiger BioPharmaceuticals Reports First Quarter 2018 Financial Results

- Hepatitis Delta Virus (HDV) Program Moving into Phase 3- Phase 2 Clinical Results Planned Across All Pipeline Programs in Second Half 2018- Existing Cash Runway Extends Through Mid-2019 (May 11, 2018)
This article is no longer available,but here are some related topics.

Page: 1

Related Keywords:Business,HDV,Law,USA, Inc.,Medicine,Surgery,Medication,Science,Lifestyle,Medical,Business,Other,


Our Privacy Policy --- @ Copyright, 2015 Digital Media Online, All Rights Reserved